Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the ‘burden of therapy’ method
| Autor: | Haas, M., Waldschmidt, D.T., Stahl, M., Reinacher-Schick, A., Freiberg-Richter, J., Fischer von Weikersthal, L., Kaiser, F., Kanzler, S., Frickhofen, N., Seufferlein, T., Dechow, T., Mahlberg, R., Malfertheiner, P., Illerhaus, G., Kubicka, S., Abdul-Ahad, A., Snijder, R., Kruger, S., Westphalen, C.B., Held, S., von Bergwelt-Baildon, M., Boeck, S., Heinemann, V. |
|---|---|
| Zdroj: | In European Journal of Cancer March 2021 146:95-106 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect